While U.S. policymakers are scaling back funding on mRNA vaccine research, Australia is accelerating investment in the technology. At the center of this effort is Moderna Inc., which is establishing an mRNA research and manufacturing footprint in the country and banking on decades of local expertise to bring new therapies to the clinic and serve as a regional hub for Asia Pacific.
Genfleet Therapeutics (Shanghai) Inc. debuted on the Hong Kong Stock Exchange on its second attempt at an IPO, raising HK$1.819 billion (US$234 million). Genfleet’s shares (HKEX:2595) rose to HK$44.00 at the opening bell on Sept. 19 and closed at HK$42.10, about 106% higher than the listing price.
Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.
South Korea’s Ministry of Food and Drug Safety announced Sept. 12 plans to significantly raise drug application fees for biosimilars but slash their review times starting next year.
Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.
South Korea’s Ministry of Food and Drug Safety announced Sept. 12 plans to significantly raise drug application fees for biosimilars but slash their review times starting next year.
Evotec International GmbH has divulged NLRP3 inflammasome modulators reported to be useful for the treatment of asthma, rheumatoid arthritis, gout, Crohn’s disease, hypertension, ulcerative colitis, metabolic and neurological disorders, among others.
NLRP3 inflammasome is a key component of the innate immune system. As a major mediator of inflammation, NLRP3 plays a central role in the pathogenesis of neurodegenerative and autoinflammatory conditions.
Heme oxygenase 1 (HO-1) is a stress-inducible enzyme that plays a critical role in the pathogenesis of rheumatoid arthritis, a systemic autoimmune disease characterized by chronic synovial inflammation, immune cell infiltration and progressive joint destruction.
Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance.
RSS
